Foghorn Therapeutics (FHTX) Non-Current Debt (2019 - 2021)

Foghorn Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $19.9 million for Q3 2021.

• On a quarterly basis, Non-Current Debt rose 126.27% year-over-year to $19.9 million in Q3 2021; TTM through Sep 2021 was $19.9 million, a 126.27% increase from a year earlier, with the FY2020 full-year figure at $19.7 million, up 79.32% from the prior year.
• Non-Current Debt held at $19.9 million in Q3 2021 per FHTX's latest filing, from $19.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $19.9 million in Q3 2021 and bottomed at $8.8 million in Q3 2020.
• The 3-year median for Non-Current Debt is $19.7 million (2020), against an average of $16.5 million.
• Across the five-year window, Non-Current Debt soared 79.32% in 2020 and jumped 126.27% in 2021, its largest moves.
• Year by year, Non-Current Debt stood at $11.0 million in 2019, then surged by 79.32% to $19.7 million in 2020, then advanced by 1.32% to $19.9 million in 2021.
• Per Business Quant, the three latest FHTX Non-Current Debt figures stand at $19.9 million (Q3 2021), $19.8 million (Q2 2021), and $19.7 million (Q1 2021).